Ligand News and Research

RSS

Study provides new knowledge about EphA2 receptor involved in several forms of cancer

Researchers at Karolinska Institutet in Sweden have headed a study that provides new knowledge about the EphA2 receptor, which is significant in several forms of cancer. This is important knowledge in itself - but just as important is how this study, which is published in the highly respected journal Nature Methods, was conducted.

8 Jul 2014

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Agenus Inc., announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.

1 Jul 2014

Genetic variants alter chance of sunitinib dose reduction

Scientists have identified genetic variants that reduce the likelihood of sunitinib dose reduction in patients with metastatic renal cell carcinoma.

30 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Healthcare Corporate Access Day to be held on June 24, 2014

ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Corporate Access Day on Tuesday, June 24, 2014, at the Dorchester Hotel in London, U.K.

11 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014

New vaccine effective at preventing lung cancer in mice

Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.

4 Jun 2014

Particular genetic variation in humans linked with blond hair

A single-letter change in the genetic code is enough to generate blond hair in humans, in dramatic contrast to our dark-haired ancestors.

2 Jun 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

S. pneumoniae interacts with other nasopharyngeal bacteria

Streptococcus pneumoniae bacteria are able to detect and respond to other bacterial species in the same host niche, researchers report in Open Biology.

12 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Nanoviricides develops new drug candidates against MERS infection

...

6 May 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

23 Apr 2014

Multifunctional microcapsules can be produced from tannic acid and metals

Microcapsules with a broad spectrum of applications in biomedicine, catalysis, and technology can be produced by using plant-derived, phenolic tannic acid and a variety of metals. The capsules are formed by a simple self-assembly process, and their properties can be controlled through the choice of metal, as demonstrated by a team of Australian and German researchers in the journal Angewandte Chemie.

16 Apr 2014

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Northwestern Medicine scientists are continuing to unravel the molecular changes that underlie one of the world's deadliest and most infamous respiratory infections.

15 Apr 2014

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

8 Apr 2014

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects.

7 Apr 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

Investigators find group of drugs to treat heart attacks and cancer metastasis

Massachusetts General Hospital (MGH) investigators may have found a way to solve a problem that has plagued a group of drugs called ligand-mimicking integrin inhibitors, which have the potential to treat conditions ranging from heart attacks to cancer metastasis.

24 Mar 2014

Proteins that regulate energy metabolism are essential for stem cell formation

Proteins that regulate energy metabolism are essential for stem cell formation, University of Washington researchers find.

21 Mar 2014